Renalytix announces highlights from publication of data on use of KidneyIntelX

Renalytix announced additional highlights from the publication of data from a clinical utility study demonstrating that use of KidneyIntelX risk assessment in the primary care setting resulted in improved clinical decision making and observed clinical outcomes for 1,686 patients in the earliest stages of diabetic kidney disease. The results published in the Journal of Primary Care and Community Health evaluated the effectiveness of a health system driven care management program focused on treating DKD patients in the earliest stages of the disease before significant loss in kidney function and other complications can develop. This study data is especially meaningful for overburdened clinical teams in the primary care community who lack accurate tools, time and resources to understand which type 2 diabetes patients are at highest risk for rapid progressive CKD decline. With KidneyIntelX risk assessment, they can adjust clinical care by optimizing medications developed to slow CKD progression, providing earlier consultation or referral to specialists, and increasing frequency of follow-up visits thereby promoting and preserving kidney function before irreversible damage occurs. The key highlights from this real-world evidence study publication include: 57% of high risk patients had action taken within 3-months, compared to 35% for low risk patients; Notably clinical observations from the study showed a nearly 10% improvement in HbA1c levels in the high risk group in the first six months. While other metrics such as eGFR and systolic blood pressure remained unchanged at the 6-month data mark, there was a 15% improvement in albuminuria, an important indicator of overall kidney health, in the low and intermediate risk groups.